A rectal probe is a small ultrasound transducer with high frequency that is inserted directly into the rectum. Transrectal ultrasound is a well established examination for rectal or prostate carcinoma assessment. Rectal probes (e.g., a microconvex probe) generate a much sharper image, caused by the close proximity to the prostate or rectum, and the higher sensitivity.

'China based Shantou Institute of Ultrasonic Instruments (SIUI) has been engaged in the development and manufacture of medical ultrasonic diagnosis scanners, industrial ultrasonic detectors and ultrasonic transducers since the early 1960's. Starting as a small scientific research institute, SIUI has developed into a key high-tech corporation at the national level, and is the leading manufacturer of ultrasonic instruments in China.'
'SIUI is dedicated to providing all customers with the ultrasonic scanners of high quality and reasonable price. The annual production amounts to 5,000 ultrasonic scanners and 10,000 transducers. SIUI takes the lead in attaining ISO9001 certification, FDA clearance and CE marking in China. Due to the high ratio of performance to price as well as the guarantee on quality, the products are exported to over 80 countries and areas around the world. The export volume ranks No. 1 in this field in China. The market share continues to improve.'

Ultrasound Systems:

From Siemens Medical Systems;
'The SONOLINE G20™ ultrasound system quickly distances itself from the competition with next-generation all-digital system architecture that utilizes Siemens technology migration. Individual imaging parameters have been optimized for a wide variety of clinical applications and patient types. So you can realize a higher degree of diagnostic confidence. Without doubt.'

From Philips Medical Systems;
'The new Philips SONOS 7500 system with Live 3D Echo is designed for superb clinical performance, improved productivity and advanced research. Now, the SONOS 7500 system becomes even more powerful with the addition of the Performance 2005 upgrade.'

Specifications for this system will be available soon.

SONUS Pharmaceuticals, Inc., is engaged in the research and development of ultrasound contrast agents (USCA) and drug delivery systems for use in the diagnosis and treatment of heart disease, cancer and other conditions.
Sonus Pharmaceuticals and OncoGenex Technologies Inc., a privately held biopharmaceutical development company, announced 2008 the signing of a definitive agreement to merge the two companies. The combined company will operate as OncoGenex Pharmaceuticals, Inc.

Ultrasound Contrast Agents: